SPRUCE BIOSCIENCES INC (SPRB)
Health Care · Orphan/rare disease biopharmaceuticals · NASDAQ
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo Syndrome Type B.
What SPRUCE BIOSCIENCES INC does
Spruce Biosciences is a clinical-stage biopharmaceutical company focused on developing therapies for rare lysosomal storage disorders. The company's lead product candidate is tralesinidase alfa enzyme replacement therapy (TA-ERT), being developed for Sanfilippo Syndrome Type B (Mucopolysaccharidosis Type IIIB / MPS IIIB). The company is pursuing regulatory approval and commercialization of TA-ERT in the United States and international markets, with plans to establish both direct commercial capabilities and third-party distribution partnerships.
Themes: ["Rare genetic disorders","Lysosomal storage diseases","Enzyme replacement therapy","Orphan drugs"]
Fundamentals
- Price$51.74 as of 2026-07-09 close
- Market cap$142M as of 2026-07-10
- 1-year return+848.6% as of 2026-07-09 close
- Net margin-1079.9% as of 2026-07-10
- ROE-155.4% as of 2026-07-10
- Debt / equity0.19 as of 2026-07-10
- Beta3.45 as of 2026-07-10
Key risks (from latest filing)
["Requires substantial additional financing; failure to secure funding could force delays or elimination of clinical development and commercialization programs.","Limited operating history with significant net losses since inception and anticipated continued losses; company may not be able to continue as a going concern.","Clinical trials may fail to demonstrate adequate efficacy and safety, preventing or delaying regulatory approval and commercialization of TA-ERT."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.